Table 1.

Patient characteristics.

Sex	Age	Stage (AJCC 2017a)	Checkpoint inhibitor	Indicationb	Comorbidities	Symptoms	Days of hospitalisation (ICUc)	Outcome
m	30	IIIB	Nivolumab	Adjuvant	None	Flu-like, dysgeusia	0	Fully recovered
m	72	IV	Nivolumab+ipilimumab	Palliative	None	Fever, flu-like, dysgeusia	0	Fully recovered
m	62	IV	Nivolumab+ipilimumab	Palliative	Cardiovascular, gastrointestinal	None	0	Asymptomatic
m	71	IV	Nivolumab+ipilimumab	Palliative	Cardiovascular, respiratory	None	0	Asymptomatic
w	65	IIIC	Pembrolizumab	Adjuvant	None	Cough	0	Fully recovered
w	83	IV	Nivolumab+ipilimumab	Adjuvant	Cardiovascular, hypothyroidism, thromboembolism	Cough, fever, dyspnoea, diarrhoea, circulatory symptoms	50(31)	Recovered with sequelae
w	65	IV	Pembrolizumab	Palliative	Cardiovascular	Cough, flu-like symptoms, dysgeusia, headache	0	Fully recovered
m	50	IV	Pembrolizumab	Palliative	None	Cough, fever, dyspnoea, diarrhoea, circulatory symptoms	0	Fully recovered
w	76	IV	Nivolumab	Adjuvant	Cardiovascular, previous cancer, hypothyroidism	Flu-like symptoms, dysgeusia, cough, headache	0	Fully recovered
m	26	IV	Pembrolizumab	Palliative	None	Dysgeusia	0	Fully recovered
w	63	IV	Nivolumab	Palliative	Hypothyroidism	Fever, diarrhoea	10	Fully recovered
w	87	IV	Nivolumab+ipilimumab	Palliative	Rheumatoid arthritis	None	0	Asymptomatic
m	88	IV	Pembrolizumab	Palliative	Hypothyroidism, haematologic, renal insufficiency, cardiovascular, thromboembolism	None	0	Asymptomatic

^aAmerican Joint Committee on Cancer.

^bPalliative: in unresectable stage III or IV disease.

^cICU, intensive care unit; m, men; w, women.